Edgewise Therapeutics, Inc.EWTXNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank43
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P43
Within normal range
vs 3Y Ago
-7.4x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-10.97%
Q3 2025-6.73%
Q2 202513.95%
Q1 2025-40.47%
Q4 20241.52%
Q3 2024-4.89%
Q2 20248.74%
Q1 2024-6.59%
Q4 2023-21.63%
Q3 2023-9.01%
Q2 202311.36%
Q1 2023-93.11%
Q4 20221.48%
Q3 202226.14%
Q2 2022-29.22%
Q1 2022-33.47%
Q4 2021-14.00%
Q3 202115.43%
Q2 2021-61.28%
Q1 2021-30.60%
Q4 2020-41.75%
Q3 202017.89%
Q2 2020-45.49%
Q1 20200.00%